Clinical Trial Update: A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating multiple doses of RO7247669 in previously untreated unresectable or metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• RO7247669

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Melanoma | Phase 2 | Status: COMPLETED